Intrexon Corp. (NYSE:XON) shares fell 3.8% during mid-day trading on Monday . The stock traded as low as $27.58 and last traded at $27.63, with a volume of 1,250,455 shares. The stock had previously closed at $28.71.

Several brokerages have issued reports on XON. Griffin Securities reiterated a “buy” rating and issued a $65.00 price target on shares of Intrexon Corp. in a report on Tuesday, June 7th. Zacks Investment Research upgraded Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $32.00 price target on the stock in a report on Tuesday, May 3rd. Wunderlich reiterated a “buy” rating and issued a $50.00 price target on shares of Intrexon Corp. in a report on Thursday, July 7th. Stifel Nicolaus reiterated a “buy” rating and issued a $57.00 price target on shares of Intrexon Corp. in a report on Wednesday, June 29th. Finally, JMP Securities restated a “buy” rating on shares of Intrexon Corp. in a report on Sunday, July 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Intrexon Corp. has an average rating of “Buy” and an average price target of $48.37.

The company has a 50 day moving average price of $25.32 and a 200 day moving average price of $29.67. The firm’s market cap is $3.20 billion.

Intrexon Corp. (NYSE:XON) last posted its earnings results on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.35. The business earned $43.40 million during the quarter, compared to analysts’ expectations of $46.26 million. During the same quarter last year, the business earned $0.25 EPS. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. Equities research analysts anticipate that Intrexon Corp. will post ($1.32) EPS for the current fiscal year.

In other news, CEO Randal J. Kirk bought 41,830 shares of Intrexon Corp. stock in a transaction on Friday, May 13th. The shares were purchased at an average price of $23.92 per share, for a total transaction of $1,000,573.60. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Several hedge funds and institutional investors have recently bought and sold shares of the company. Trexquant Investment LP purchased a new position in Intrexon Corp. during the fourth quarter worth $2,590,000. New York State Common Retirement Fund increased its stake in Intrexon Corp. by 30.1% in the fourth quarter. New York State Common Retirement Fund now owns 212,875 shares of the company’s stock valued at $6,418,000 after buying an additional 49,290 shares during the last quarter. Swiss National Bank increased its stake in Intrexon Corp. by 3.8% in the fourth quarter. Swiss National Bank now owns 62,500 shares of the company’s stock valued at $1,884,000 after buying an additional 2,300 shares during the last quarter. Rhumbline Advisers increased its stake in Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock valued at $1,387,000 after buying an additional 2,890 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its stake in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock valued at $1,068,000 after buying an additional 880 shares during the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.